OSTAMAN D3 is a high-strength vitamin D₃ preparation designed for rapid repletion or maintenance of vitamin D stores. The active ingredient, cholecalciferol 60,000 IU, is presented in a nanodroplet formulation that improves solubility and intestinal absorption compared with conventional oil drops. The product uses a flavoured, sugar-free base to make administration easier and suitable for patients who need to avoid added sugars.
OSTAMAN D3 is intended for use when a clinician determines that high-dose vitamin D supplementation is required, for example in documented vitamin D deficiency, in the initial repletion phase prior to maintenance therapy, or as part of a treatment plan for osteopenia or osteoporosis. It may also be used when faster restoration of 25-hydroxyvitamin D levels is desired or when absorption from standard formulations is suboptimal.
Cholecalciferol is converted in the liver to 25-hydroxyvitamin D and then in the kidney to the biologically active form, 1,25-dihydroxyvitamin D. Active vitamin D increases intestinal absorption of calcium and phosphate, supports bone mineralisation and normal muscle function, and contributes to certain immune and metabolic processes. The nanodroplet vehicle enhances dispersion and may increase bioavailability compared with traditional oil suspensions.
Use OSTAMAN D3 only as directed by a healthcare professional. The product is a concentrated formulation and dosing frequency, duration and total number of doses should be decided by the prescriber based on baseline vitamin D status, age, comorbidities and concurrent therapies. Do not self-dose. A healthcare professional will provide a specific regimen (for example, a single supervised high-dose administration or a short course) and arrange follow-up testing to confirm repletion and determine maintenance needs.
Do not use OSTAMAN D3 in patients with known hypersensitivity to cholecalciferol or any ingredient of the formulation. Exercise caution and seek specialist advice before use in patients with granulomatous diseases (for example sarcoidosis), some lymphomas, uncontrolled hyperparathyroidism, severe renal impairment, or other disorders of calcium metabolism, as such conditions can increase the risk of hypercalcaemia with high-dose vitamin D. Inform your prescriber about all medications and supplements you take.
Vitamin D status and calcium handling can be affected by several medicines. Interactions of clinical importance include thiazide diuretics (which can increase risk of hypercalcaemia), certain anticonvulsants and glucocorticoids (which may alter vitamin D metabolism), and concurrent high-dose calcium or mineral supplements. Your clinician will check for interacting drugs and adjust treatment or monitoring as needed.
When used as prescribed, OSTAMAN D3 is usually well tolerated. Excessive or prolonged high dosing can cause hypercalcaemia with symptoms such as nausea, vomiting, excessive thirst, polyuria, weakness or confusion; if any of these occur, stop treatment and seek medical advice immediately. Allergic reactions are uncommon but possible; discontinue and seek help if rash, swelling or breathing difficulty develops. Regular monitoring of serum calcium and 25-hydroxyvitamin D is recommended for high-dose regimens or in patients at increased risk.
Store OSTAMAN D3 in a cool, dry place away from direct sunlight and heat. Keep the bottle tightly closed when not in use. Do not refrigerate unless the product label specifies otherwise. Keep out of reach of children and do not use beyond the expiry date printed on the pack.
Contact your physician if you are pregnant or breastfeeding, have kidney disease, known disorders of calcium metabolism, or if you are taking other medications that may interact with vitamin D. Seek immediate medical attention for severe symptoms suggestive of hypercalcaemia, allergic reaction, or any unexpected serious adverse event.
© 2024-25, JAZMEDS Healthcare, All rights reserved
